AbbVie and Gubra Announce License Agreement to Develop an Amylin Analog for the Treatment of Obesity ...Middle East

PR Newswire - News
AbbVie and Gubra Announce License Agreement to Develop an Amylin Analog for the Treatment of Obesity

Partnership marks AbbVie's entrance into the obesity field Agreement will enable the incorporation of GUB014295, an amylin peptide discovered and developed by Gubra, into AbbVie's global infrastructure for developing and commercializing therapies for patients in need NORTH CHICAGO, Ill....

    Read More Details
    Finally We wish PressBee provided you with enough information of ( AbbVie and Gubra Announce License Agreement to Develop an Amylin Analog for the Treatment of Obesity )

    Apple Storegoogle play

    Also on site :

    Most viewed in News